Kadcyla Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche Switzerland Originator | GLT

Generic Information: Kadcyla (Switzerland)

Kadcyla is the originator ado-trastuzumab emtansine from Roche, a HER2-directed antibody-drug conjugate supplied as a sterile lyophilized powder in single-use vials of 100 mg and 160 mg. This Switzerland-sourced presentation carries the reference-standard provenance of the product first approved by the US FDA in 2013. Each vial is reconstituted to a 20 mg/mL solution for intravenous infusion, and the product travels under controlled cold-chain conditions because it is a temperature-sensitive biologic.

What Is Ado-trastuzumab Emtansine (Kadcyla) Used For?

Kadcyla treats HER2-positive breast cancer in two settings. In metastatic disease it is given as a single agent to patients whose cancer has progressed after trastuzumab and a taxane, based on the landmark EMILIA trial that showed a meaningful survival gain. In early disease it is used as adjuvant therapy for patients left with residual invasive cancer after neoadjuvant taxane plus trastuzumab, where the KATHERINE trial demonstrated it roughly halved the risk of recurrence or death compared with continuing trastuzumab alone.

How Does Kadcyla Work?

Kadcyla fuses two anticancer weapons into one molecule. The trastuzumab antibody seeks out the HER2 receptor over-expressed on the tumour cell, then the whole conjugate is drawn inside the cell. There the stable linker releases DM1, a highly potent microtubule inhibitor, which stops the cell dividing and drives it toward death. Because the chemotherapy is delivered only into HER2-positive cells, healthy tissue is spared much of the exposure that free DM1 would otherwise cause.

Indications

The approved indications are, first, HER2-positive metastatic breast cancer in adults who have already received trastuzumab and a taxane, either separately or in combination, and, second, the adjuvant treatment of HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy containing a taxane and trastuzumab. Treatment selection is guided by a validated HER2 test, and the medicine is given as monotherapy — it is not combined with other chemotherapy agents in these indications.

Dosage

The standard dose is 3.6 mg per kilogram of body weight, given by intravenous infusion every three weeks until disease progression or unacceptable toxicity. The 100 mg and 160 mg vial sizes let the pharmacy round doses efficiently; a typical patient needs more than one vial per cycle, which is why both strengths exist. The first infusion is given over 90 minutes, and later infusions over 30 minutes if the earlier doses were well tolerated.

Side Effects

Common effects include fatigue, nausea, muscle and joint pain, headache, and low platelet counts. The boxed warnings cover serious liver injury, heart toxicity from reduced left-ventricular function, and harm to a developing fetus, so liver enzymes and heart function are monitored before and during treatment. Bleeding risk from thrombocytopenia means platelet counts are checked before each dose.

Storage

Kadcyla vials are stored refrigerated at 2°C to 8°C and protected from light until reconstitution, and the product is a cold-chain biologic. GLT ships it through validated temperature-controlled logistics from a Hong Kong-licensed facility, with batch documentation and a certificate of analysis enclosed.

Why Choose Kadcyla Through GLT?

The Swiss originator presentation offers Roche's reference-standard T-DM1 with European provenance and full traceability, the benchmark against which biosimilars are compared. For hospitals and importing pharmacies that require the innovator molecule, GLT's Hong Kong base provides documented cold-chain access and dependable cross-border supply.

How to Order

To order Kadcyla (ado-trastuzumab emtansine) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, vial size and cold-chain delivery timelines to your country, and dispatch from a Hong Kong-licensed facility.

FAQ

Is Kadcyla the original T-DM1? Yes — Kadcyla is Roche's originator ado-trastuzumab emtansine, first approved in 2013 and still the reference ADC.

Why are there two vial sizes? The 100 mg and 160 mg vials let pharmacists round a 3.6 mg/kg dose efficiently, since most patients need more than one vial per cycle.

Does it need cold storage? Yes — it is a refrigerated biologic shipped by validated cold chain at 2°C to 8°C.